Plain-English translation of NCT05336695 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers are using a new imaging tool called PET to measure levels of fibrin (a protein involved in blood clotting) in the brains of people with memory problems and people without memory problems. Fibrin may play a role in Alzheimer's disease and related dementias, but scientists have never been able to directly measure it in living brains before. This study will help researchers understand whether fibrin is connected to memory loss.
Alzheimer's disease and related dementias have no cure, and scientists still don't fully understand what causes them. Growing evidence suggests that fibrin may contribute to these diseases, but there's been no way to safely measure it in a living person's brain until now.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would come in for brain imaging scans using the new PET tool, which takes pictures of your brain to measure fibrin levels. You may also have an MRI scan and undergo memory testing. The study is comparing results between people without memory problems and people with Alzheimer's disease or related memory disorders to see if fibrin levels differ between these groups.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States